Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GreenLight Biosciences and Samsung Biologics Announce Collaboration to Build Capacity for Messenger RNA Vaccine Manufacturing

11/24/2021 | 07:00am EST

GreenLight Biosciences and Environmental Impact Acquisition Corp. and Samsung Biologics announced a partnership agreement in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale. The partnership aims to accelerate production of GreenLight's COVID-19 vaccine candidate for Phase III clinical trials and, subject to regulatory approval, commercial sales. The collaboration with Samsung will leverage GreenLight's existing manufacturing process, with technology transfer from GreenLight to Samsung starting immediately. Both Samsung Biologics and GreenLight are committed to vaccine equity and envision a world capable of producing enough messenger RNA vaccine doses for billions of people a year. This supports GreenLight's ambition to help vaccinate the world against COVID-19, as detailed in its Blueprint To Vaccinate The World published in March 2021. This vision aligns with calls by CEPI, and others for concrete actions to increase vaccine manufacturing capacity across the world, not just for COVID-19, but also for other infectious diseases reflecting the ongoing global health needs. Samsung Biologics has been proactive in accommodating client needs in the biopharma CDMO landscape, including its plans to add messenger RNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022.


© S&P Capital IQ 2021
All news about SAMSUNG BIOLOGICS CO.,LTD.
02:10aS.Korea stocks hit 7-week closing low ahead of LGES IPO
RE
02:05aSAMSUNG BIOLOGICS : Prior Notice on Disclosure of Final Earnings
PU
01/14South Korean Stocks Fall for Second Day as Bank of Korea Raises Base Rate; Samsung Biol..
MT
01/13Samsung Biologics to Start Building Fifth Plant to Meet Higher Biopharmaceutical Produc..
MT
01/13S.Korean stocks end lower on options expiry; BOK in focus
RE
01/12South Korean Stocks Jump After US Fed Chief’s Less Hawkish Testimony; Hanmi Pharm..
MT
01/12S.Korean stocks post best day in 6 weeks on Powell remarks
RE
01/03S.Korea stocks begin 2022 with mild gains on trade data boost
RE
2021Wall Street closes down, indexes still poised for big annual gains
RE
2021Samsung BioLogics says report on Biogen deal talks untrue
RE
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2021 1 552 B 1,30 B 1,30 B
Net income 2021 437 B 0,37 B 0,37 B
Net Debt 2021 248 B 0,21 B 0,21 B
P/E ratio 2021 125x
Yield 2021 -
Capitalization 53 329 B 44 750 M 44 743 M
EV / Sales 2021 34,5x
EV / Sales 2022 29,8x
Nbr of Employees 2 886
Free-Float 25,0%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | A207940 | KR7207940008 | MarketScreener
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 826 000,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Seok-Woo Jung Independent Director
Sector and Competitors